HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

AbstractUNLABELLED:
Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival. Dosimetric calculations in relation to PRRT have been concentrated to normal organ dosimetry in order to limit side effects. However, the relation between the absorbed dose to the tumor and treatment response has so far not been established. Better knowledge in this respect may improve the understanding of treatment effects, allow for improved selection of those patients who are expected to benefit from PRRT, and avoid unnecessary treatments. The aim of the present work was to evaluate the dose-response relationship for pancreatic neuroendocrine tumors treated with PRRT using (177)Lu-DOTATATE.
METHODS:
Tumor-absorbed dose calculations were performed for 24 lesions in 24 patients with metastasized pancreatic neuroendocrine tumors treated with repeated cycles of (177)Lu-DOTATATE at 8-wk intervals. The absorbed dose calculations relied on sequential SPECT/CT imaging at 24, 96, and 168 h after infusion of (177)Lu-DOTATATE. The unit density sphere model from OLINDA was used for absorbed dose calculations. The absorbed doses were corrected for partial-volume effect based on phantom measurements. On the basis of these results, only tumors larger than 2.2 cm in diameter at any time during the treatment were included for analysis. To further decrease the effect of partial-volume effect, a subgroup of tumors (>4.0 cm) was analyzed separately. Tumor response was evaluated by CT using Response Evaluation Criteria In Solid Tumors.
RESULTS:
Tumor-absorbed doses until best response ranged approximately from 10 to 340 Gy. A 2-parameter sigmoid fit was fitted to the data, and a significant correlation between the absorbed dose and tumor reduction was found, with a Pearson correlation coefficient (R(2)) of 0.64 for tumors larger than 2.2 cm and 0.91 for the subgroup of tumors larger than 4.0 cm. The largest tumor reduction was 57% after a total absorbed dose of 170 Gy.
CONCLUSION:
The results imply a significant correlation between absorbed dose and tumor reduction. However, further studies are necessary to address the large variations in response for similar absorbed doses.
AuthorsEzgi Ilan, Mattias Sandström, Cecilia Wassberg, Anders Sundin, Ulrike Garske-Román, Barbro Eriksson, Dan Granberg, Mark Lubberink
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 56 Issue 2 Pg. 177-82 (Feb 2015) ISSN: 1535-5667 [Electronic] United States
PMID25593115 (Publication Type: Journal Article)
Copyright© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Chemical References
  • 177Lu-octreotide, DOTA(0)-Tyr(3)-
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Peptide
  • Octreotide
Topics
  • Adult
  • Aged
  • Dose-Response Relationship, Radiation
  • Female
  • Humans
  • Image Processing, Computer-Assisted
  • Kidney (drug effects, radiation effects)
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neuroendocrine Tumors (radiotherapy)
  • Octreotide (analogs & derivatives, therapeutic use)
  • Pancreatic Neoplasms (radiotherapy)
  • Positron-Emission Tomography
  • Prospective Studies
  • Radioisotopes (therapeutic use)
  • Radiometry
  • Radionuclide Imaging
  • Radiopharmaceuticals (therapeutic use)
  • Receptors, Peptide (chemistry)
  • Time Factors
  • Tomography, Emission-Computed, Single-Photon
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: